Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Blood
Barbara WassmannOliver Ottmann

Abstract

The best strategy for incorporating imatinib in front-line treatment of Ph+ acute lymphoblastic leukemia (ALL) has not been established. We enrolled 92 patients with newly diagnosed Ph+ ALL in a prospective, multicenter study to investigate sequentially 2 treatment schedules with imatinib administered concurrent to or alternating with a uniform induction and consolidation regimen. Coadministration of imatinib and induction cycle 2 (INDII) resulted in a complete remission (CR) rate of 95% and polymerase chain reaction (PCR) negativity for BCR-ABL in 52% of patients, compared with 19% in patients in the alternating treatment cohort (P = .01). Remarkably, patients with and without a CR after induction cycle 1 (INDI) had similar hematologic and molecular responses after concurrent imatinib and INDII. In the concurrent cohort, grades III and IV cytopenias and transient hepatotoxicity necessitated interruption of induction in 87% and 53% of patients, respectively; however, duration of induction was not prolonged when compared with patients receiving chemotherapy alone. No imatinib-related severe hematologic or nonhematologic toxicities were noted with the alternating schedule. In each cohort, 77% of patients underwent allogeneic stem...Continue Reading

Associated Clinical Trials

Citations

Mar 12, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·N Gökbuget, D Hoelzer
Jul 1, 2007·Current Hematologic Malignancy Reports·Farhad RavandiHagop Kantarjian
Jul 1, 2007·Current Hematologic Malignancy Reports·Deborah A ThomasHagop Kantarjian
Jul 1, 2008·Current Hematologic Malignancy Reports·Daniel J DeAngelo, Richard M Stone
Jun 11, 2011·Current Hematologic Malignancy Reports·Michael S MathisenFarhad Ravandi
Mar 12, 2013·Current Hematologic Malignancy Reports·A K Fielding, G A Zakout
Sep 1, 2006·Current Hematologic Malignancy Reports·Ryuzo Ohno, UNKNOWN Japan Adult Leukemia Study Group
Jun 7, 2012·Current Oncology Reports·Theresa Liu-DumlaoFarhad Ravandi
Dec 19, 2008·International Journal of Hematology·Masamitsu YanadaTomoki Naoe
Mar 13, 2008·Bone Marrow Transplantation·A Stein, S J Forman
Nov 13, 2007·Bone Marrow Transplantation·P A Mehta, S M Davies
Mar 17, 2012·Japanese Journal of Clinical Oncology·Teruhisa AzumaUNKNOWN Japan Clinical Oncology Group-Lymphoma Study Group (JCOG-LSG), Tokyo, Japan
Jul 9, 2009·Current Opinion in Oncology·Oliver G Ottmann, Heike Pfeifer
Jun 10, 2008·Current Opinion in Hematology·Sarah Larson, Wendy Stock
Aug 3, 2007·The Journal of Clinical Investigation·Daniel W Sherbenou, Brian J Druker
Dec 17, 2009·Hematology·Oliver G Ottmann, Heike Pfeifer
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirk R SchultzBruce Camitta
Sep 15, 2011·Drugs & Aging·Philippe Rousselot, André Delannoy
Feb 11, 2010·Haematologica·Albert OriolUNKNOWN Programa Español de Tratamiento en Hematologia Group
Dec 26, 2013·Leukemia Research·Osamu TomitaNobutaka Kiyokawa
Jun 26, 2014·Chemotherapy Research and Practice·Nida Iqbal, Naveed Iqbal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.